BioCat and ALPCO Diagnostics Sign Exclusive Distribution Agreement
ALPCO Diagnostics is renowned for their insulin ELISA kits and other market-leading metabolism assays. The ALPCO assays cover all aspects of metabolism and associated diseases, for example assays for factors involved in diabetes and obesity or cardiovascular diseases.
Dr. Michael Ehret, CEO at BioCat comments: "Thanks to the outstanding quality of the ALPCO ELISA kits we were able to build a solid customer base in the past. The exclusive distribution agreement will bring this collaboration to a new level."
Karen Stein, Vice President of Sales and Marketing for ALPCO Diagnostics, stated: "We are very excited to have BioCat as our exclusive distributor in Germany. They are well known for their commitment to life science research and their excellent technical support, making them an ideal partner to represent ALPCO in Germany."
About ALPCO Diagnostics
ALPCO Diagnostics (Salem, NH, U.S.A) provides industry-leading metabolism immunoassays for use in a number of diagnostic and research areas with focus on metabolites involved in diabetes and obesity, cardiovascular diseases, kidney injury, bone metabolism and many more. Their kits are developed by scientists committed to supporting scientists. This is clearly reflected by the quality and the versatile panel of immunoassays for metabolic disease research.
BioCat GmbH (Heidelberg, Germany) supplies the scientific community with innovative and high quality kits and reagents. BioCat's product portfolio provides modular solution packages to help deciphering the complex regulation of biological networks.
Press releases you might also be interested in
Weitere Informationen zum Thema "Biotechnik":
Neue Herausforderungen bei IoT, Security und KI
Im Jahr 2018 werden anspruchsvolle IoT-Anwendungen die Grenzen der Datenverarbeitung weiter verschieben und IT-Sicherheitsforscher verstärkt selbst ins Visier geraten. Außerdem wird man maschinellem Lernen und künstlicher Intelligenz mit weniger Skepsis begegnen.Weiterlesen